Compare EBMT & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EBMT | TTRX |
|---|---|---|
| Founded | 1922 | 2015 |
| Country | United States | United States |
| Employees | N/A | 2 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 182.5M | 174.9M |
| IPO Year | 2009 | N/A |
| Metric | EBMT | TTRX |
|---|---|---|
| Price | $23.36 | $9.62 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $24.00 | $8.00 |
| AVG Volume (30 Days) | ★ 100.3K | 86.0K |
| Earning Date | 04-28-2026 | 05-31-2026 |
| Dividend Yield | ★ 2.55% | N/A |
| EPS Growth | ★ 53.23 | N/A |
| EPS | ★ 0.51 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.00 | N/A |
| P/E Ratio | $45.47 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.50 | $2.57 |
| 52 Week High | $24.66 | $11.69 |
| Indicator | EBMT | TTRX |
|---|---|---|
| Relative Strength Index (RSI) | 51.17 | 72.73 |
| Support Level | $21.59 | $4.40 |
| Resistance Level | $24.10 | N/A |
| Average True Range (ATR) | 0.75 | 0.99 |
| MACD | -0.09 | 0.24 |
| Stochastic Oscillator | 22.78 | 63.82 |
Eagle Bancorp Montana Inc operates as a bank holding company. It provides loan and deposit services. The company focuses on residential loans, commercial real estate loans, commercial loans, consumer loans, and home equity loan products. The bank also offers deposit accounts which include checking, savings, money market, individual retirement accounts, and certificates of deposit accounts. It is a diversified lender with a focus on residential mortgage loans, commercial real estate mortgage loans, commercial business loans, agricultural loans, and second mortgage/home equity loan products.
Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.